Samsung Bioepis Taps Infliximab As Its US Biosimilar Pioneer
This article was originally published in PharmAsia News
A month after the US FDA granted approval of Celltrion's biosimilar infliximab, another South Korean firm, Samsung Bioepis, is rapidly progressing its diverse pipeline and is seeking an entry into the US market through an approval filing for its biosimilar version of the anti-inflammatory antibody. The product is already available in South Korea and recently won a green light in Europe.
You may also be interested in...
Agency has scheduled only two advisory committee meetings in 2017; does it indicate the agency plans to conduct fewer meetings going forward?
For the South Korean pharma industry, 2016 was largely about major global advances for a wide range of biosimilars, accompanied but some setbacks in the area of novel drug development.
After receiving regulatory approvals in Europe for its biosimilar versions of etanercept and infliximab earlier this year, South Korea's Samsung Bioepis is now looking to add adalimumab to it and partner Biogen’s growing portfolio.